Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan P Piccini

Showing results (461-470 of 538) with videos related to

Pageof 54
Sort By:
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experienceKenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|April 23, 2021
GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillationKeith A A Fox, Saverio Virdone, Karen S Pieper, et al.
European Heart Journal|September 12, 2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF TrialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Heart Rhythm|August 14, 2018
Updated performance of the Micra transcatheter pacemaker in the real-world setting: A comparison to the investigational study and a transvenous historical controlMikhael F El-Chami, Faisal Al-Samadi, Nicolas Clementy, et al.
American Heart Journal|December 21, 2021
Achievement and quality measure attainment in patients hospitalized with atrial fibrillation: Results from The Get With The Guidelines - Atrial Fibrillation (GWTG-AFIB) registryAditya J Ullal, DaJuanicia N Holmes, Barbara L Lytle, et al.
Heart Rhythm O2|March 4, 2022
Dose-limiting, adverse event-associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trialWilliam T Abraham, Jonathan P Piccini, Christopher Dufton, et al.
Circulation. Arrhythmia and Electrophysiology|November 11, 2023
Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201)A John Camm, Jonathan P Piccini, Marco Alings, et al.
The American Journal of Cardiology|August 23, 2020
Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF)Malini Madhavan, DaJuanicia N Holmes, Jonathan P Piccini, et al.
Lancet (London, England)|June 18, 2023
Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trialBruce S Stambler, A John Camm, Marco Alings, et al.
Circulation|February 9, 2022
MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 TrialKarl Georg Haeusler, Felizitas A Eichner, Peter U Heuschmann, et al.
Pageof 54

Showing results (461-470 of 538) with videos related to

Sort By:
Pageof 54
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experienceKenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|April 23, 2021
GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillationKeith A A Fox, Saverio Virdone, Karen S Pieper, et al.
European Heart Journal|September 12, 2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF TrialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Heart Rhythm|August 14, 2018
Updated performance of the Micra transcatheter pacemaker in the real-world setting: A comparison to the investigational study and a transvenous historical controlMikhael F El-Chami, Faisal Al-Samadi, Nicolas Clementy, et al.
American Heart Journal|December 21, 2021
Achievement and quality measure attainment in patients hospitalized with atrial fibrillation: Results from The Get With The Guidelines - Atrial Fibrillation (GWTG-AFIB) registryAditya J Ullal, DaJuanicia N Holmes, Barbara L Lytle, et al.
Heart Rhythm O2|March 4, 2022
Dose-limiting, adverse event-associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trialWilliam T Abraham, Jonathan P Piccini, Christopher Dufton, et al.
Circulation. Arrhythmia and Electrophysiology|November 11, 2023
Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201)A John Camm, Jonathan P Piccini, Marco Alings, et al.
The American Journal of Cardiology|August 23, 2020
Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF)Malini Madhavan, DaJuanicia N Holmes, Jonathan P Piccini, et al.
Lancet (London, England)|June 18, 2023
Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trialBruce S Stambler, A John Camm, Marco Alings, et al.
Circulation|February 9, 2022
MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 TrialKarl Georg Haeusler, Felizitas A Eichner, Peter U Heuschmann, et al.
Pageof 54